BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lickliter JD, Gan HK, Voskoboynik M, Arulananda S, Gao B, Nagrial A, Grimison P, Harrison M, Zou J, Zhang L, Luo S, Lahn M, Kallender H, Mannucci A, Somma C, Woods K, Behren A, Fernandez-Penas P, Millward M, Meniawy T. A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. Drug Des Devel Ther 2020;14:1177-89. [PMID: 32256049 DOI: 10.2147/DDDT.S243787] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Lv W, Cheng K, Li X, Feng L, Li H, Li J, Chang C, Cao D. Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein-Barr Virus-Associated Gastric Cancer. Front Oncol 2021;11:759652. [PMID: 35096571 DOI: 10.3389/fonc.2021.759652] [Reference Citation Analysis]
2 Wang CY, Sheng CC, Ma GL, Xu D, Liu XQ, Wang YY, Zhang L, Cui CL, Xu BH, Song YQ, Zhu J, Jiao Z. Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy. Acta Pharmacol Sin 2021;42:1368-75. [PMID: 33154554 DOI: 10.1038/s41401-020-00550-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Xu B, Sun HC. Camrelizumab: an investigational agent for hepatocellular carcinoma. Expert Opin Investig Drugs 2021;:1-10. [PMID: 34937475 DOI: 10.1080/13543784.2022.2022121] [Reference Citation Analysis]
4 Jiang P, Geng L, Mao Z, Wang Q, Wang W, Jiao M, Yao Y, Chen N, Zhang J, Nan K, Shen Y, Guo H, Jiang L. First-line chemotherapy plus immune checkpoint inhibitors or bevacizumab in advanced non-squamous non-small-cell lung cancer without EGFR mutations or ALK fusions. Immunotherapy 2022. [PMID: 35259921 DOI: 10.2217/imt-2021-0112] [Reference Citation Analysis]
5 Araujo DV, Uchoa B, Soto-Castillo JJ, Furlan LL, Oliva M. When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents. Target Oncol 2022;17:253-70. [PMID: 35687223 DOI: 10.1007/s11523-022-00890-1] [Reference Citation Analysis]
6 Cunningham O, Scott M, Zhou ZS, Finlay WJJ. Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns. MAbs 2021;13:1999195. [PMID: 34780320 DOI: 10.1080/19420862.2021.1999195] [Reference Citation Analysis]
7 Liu L, Liu Y, Gong L, Zhang M, Wu W. Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature. Cancer Biol Ther 2020;21:983-9. [PMID: 33092443 DOI: 10.1080/15384047.2020.1829265] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Hwang K, Yoon JH, Lee JH, Lee S. Recent Advances in Monoclonal Antibody Therapy for Colorectal Cancers. Biomedicines 2021;9:39. [PMID: 33466394 DOI: 10.3390/biomedicines9010039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]